Answer each question to find trials that best match your clinical situation. You can leave questions blank if you do not know the answer.
This search will output a list of trials for which you may be eligible based on the criteria you enter.
For more detailed information please click on the clinical trial number and you will be taken to the clinicaltrials.gov website.
For a key to the icons and text used in the Results column, please click here.
To learn more about our trial annotation process, results assignments, and the criteria used to highlight drugs with promising results, please click here.
|NCT02033616||II||Newly diagnosed stage III/IV ovarian cancer or stage III/IV ovarian cancer after completion of first-line therapy||Phase II, Double-Blind, Randomized Trial Of AVOVA-1 (Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens) Vs. Autologous Peripheral Blood Mononuclear Cells (MC) In Patients With Stage III Or IV Epithelial Ovarian, Fallopian Tube Or Primary Peritoneal Carcinoma After Primary Therapy||CA, CO||View Drugs||View Results |
|AVOVA-1||TAA-loaded autologous dendritic cell vaccine, Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens||Immune response against tumor-associated antigens||Clinical Trials|
|NCT03735589||I/II||Newly diagnosed stage II-IV ovarian cancer that responded to first-line platinum therapy||A Phase I/IIa Safety and Immunologic Efficacy Trial of Intraperitoneal Induction of CTLs Combined With Alpha-Dendritic Cell Vaccine for Primary Ovarian Cancer||NY||View Drugs|
|Alpha-DC1 vaccine||Immune response against tumor-associated antigens||Clinical Trials|
|Autologous nCTLs||Autologous Natural Killer Cell-like nCTLs, autologous natural killer-like cytotoxic lymphocytes, autologous aDC1-induced CTLs||Anti-tumor immune response||Clinical Trials|
|NCT03054909||I||Stage III/IV ovarian cancer with stable disease or better after first-line IV/IP cisplatin and paclitaxel therapy (maintenance)||QUILT-2.021: Randomized Study of Single Course of Intraperitoneal (IP) ALT-803 Followed by Subcutaneous (SQ) Maintenance ALT-803 Versus Subcutaneous (SQ) Maintenance ALT-803 Only After 1st Line Chemotherapy for Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancer||MN||View Drugs||View Results |
|N-803||superagonist interleukin-15:interleukin-15 receptor alphaSu/Fc fusion complex N-803, ALT-803||IL-15 receptor agonist||Clinical Trials|
|NCT03839524||I||High grade serous ovarian cancer with complete response after first-line platinum therapy (w/ banked tumor tissue)||A Phase I Trial Evaluating a Mutanome-directed Immunotherapy in Patients With High Grade Serous Carcinoma (HGSC) of the Ovary, Fallopian Tube or Peritoneum.||AZ, FL, MN||View Drugs|
|TG4050||MyVAC, Modified Vaccinia Ankara (MVA) personalized vaccine||Immune response against tumor-associated antigens||Clinical Trials|
|NCT04367675||I||Ovarian cancer with no evidence of disease after first-line treatment||Phase 1b Study of INO-5401 Alone or INO-5401 in Combination With INO-9012 Followed by Electroporation in Adult Cancer and Non-Cancer Patients With BRCA1 or BRCA2 Mutations||Contact research study staff||View Drugs|
|INO-5401||WT1/PSMA/hTERT-encoding plasmid DNA INO-5401||Immune response against cancer expressing hTERT, PMSA or WT1||Clinical Trials|
|INO-9012||DNA plasmid encoding interleukin-12 INO-9012||IL-12 receptor agonist||Clinical Trials|